bc8
mAbexperimentalADC
Clinical trial activity
10 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Feb 1, 1999 (NCT00003868)
Timeline
Indications
Studied for
- Allogeneic Cells · Phase 2/Phase 3
- Anemia, Refractory · Phase 2
- Antigens, CD · Phase 1
- Bone Marrow Transplantation · Phase 3
- Glomerular Basement Membrane · Early Phase 1
- Hodgkin Disease · Phase 1
- Leukemia · Phase 2
- Leukemia, Lymphoid · Early Phase 1
- Leukemia, Myeloid · Phase 2/Phase 3
- Leukemia, Myeloid, Acute · Phase 3
- Leukemia, Myelomonocytic, Chronic · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Early Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Early Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Myelodysplastic Syndromes · Phase 2
- Neoplasms, Germ Cell and Embryonal · Early Phase 1
- Organ Transplantation · Phase 2/Phase 3
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Thrombocytopenia · Phase 2
Mechanism of action
- Leukocyte common antigenBINDING AGENT
PTPRC binding agent
- Leukocyte common antigenINHIBITOR
PTPRC inhibitor
- Unspecified targetRadiodepletion
radiodepletion
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- 131-iodine
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109630 ↗
Also known as
- bc8
- bc8
- bc8
- bc8 131i
- iomab-b
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07157514 | Phase 2/Phase 3 (Phase 3) | Jan 31, 2026 | Actinium Pharmaceuticals |
| NCT04512716 | Early Phase 1 (Phase 1) | Feb 2, 2021 | Actinium Pharmaceuticals, Memorial Sloan-Kettering Cancer Center |
| NCT02665065 | Phase 3 | Jun 1, 2016 | Actinium Pharmaceuticals |
| NCT00860171 | Phase 1 | Feb 1, 2009 | National Cancer Institute (NCI), University of Washington |
| NCT00589316 | Phase 1 | Oct 5, 2007 | National Cancer Institute (NCI), University of Washington |
| NCT00119366 | Phase 2 | May 1, 2003 | National Cancer Institute (NCI), University of Washington |
| NCT00005940 | Phase 2 | Oct 1, 1999 | National Cancer Institute (NCI), University of Washington |
| NCT00008177 | Phase 1 | Jul 1, 1999 | National Cancer Institute (NCI), University of Washington |
| NCT00003868 | Phase 2 | Feb 1, 1999 | National Cancer Institute (NCI), University of Washington |
| NCT00003870 | Phase 2 | Feb 1, 1999 | National Cancer Institute (NCI), University of Washington |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 7 | 0 | 2 | 1999 |
| University of Washington | Academic/Hospital | 7 | 7 | 2 | 1999 |
| Actinium Pharmaceuticals | For profit | 3 | 2 | 2 | 2016 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1